Hodgkin s lymphoma is a malignant tumor that develops from cells in the lymphatic system called lymphocytes. The cancer is characterized histologically by the presence of multinucleated giant cells called Reed-Sternberg cells and associated abnormal, smaller mononuclear cells originating from B-lymphocytes in the germinal centers of lymphoid tissue. Global statistics show that the number of new cases of Hodgkin’s lymphoma is 2.6 per 100,000 men and women, per year. Unlike most cancers, the chances of Hodgkin’s lymphoma do not increase with age; they are found to be high in two age groups, young adults and the elderly. The increase in the number of new cases diagnosed every year is expected to drive the Hodgkin’s lymphoma treatment market.
Key Market Trends
Radiotherapy Segment is Expected to Register a Significant Growth over the Forecast Period
Based on Treatment Type, it is segmented into Chemotherapy, Radiotherapy, and Others. Radiotherapy is a well-established technique at destroying Hodgkin’s disease cells by using high-energy beams or particles to kill cancer cells and may be delivered from a source outside the body, i.e., external beam radiation or internally, such as brachytherapy. For classical Hodgkin’s disease, radiotherapy is often given after chemotherapy, especially when there is a large or bulky tumor mass. According to the American Cancer Society, in 2019, around 8,110 people in the United States were diagnosed with Hodgkin lymphoma. Hence, the rising burden of cancer, along with increasing awareness about hodgkin s lymphoma, the market is expected to grow in the forecast period.
North America Expected to Hold the Largest Share in the Hodgkin Lymphoma Treatment Market
The hodgkin lymphoma treatment market expected to hold the largest share in the North America region. According to the American Cancer Society estimates, in 2019, there were around 1,000 deaths (410 women and 590 men) from Hodgkin’s lymphoma in the United States. Hodgkin lymphoma affects both children and adults. It is the most commonly diagnosed cancer in teens aged 15 to 19 years. The increasing number of new cases, developed healthcare infrastructure and advanced treatment options are contributing to the growth of the studied market.
The global players into the hodgkin lymphoma treatment market are Alkem Laboratories, Amneal Pharmaceuticals, Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, Incyte Corp, Merck & Co. Inc., Seattle Genetics, Inc. and Teva Pharmaceutical Industries Ltd.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Hodgkin Lymphoma
4.2.2 Increasing Awareness about Hodgkin Lymphoma
4.2.3 High Unmet Need in Older Patients and Patients with Relapsed or Refractory (R/R) HL
4.3 Market Restraints
4.3.1 Adverse Long-term Side Effects
4.3.2 High Cost of Treatment
4.4 Porter s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment Type
5.2.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle-East and Africa
5.2.5 South America
22.214.171.124 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Alkem Laboratories
6.1.2 Amneal Pharmaceuticals, Inc.
6.1.3 Baxter International Inc.
6.1.4 Biogen Inc.
6.1.5 Bristol-Myers Squibb Company
6.1.6 F Hoffmann-La Roche Ltd
6.1.7 Incyte Corp
6.1.8 Merck & Co. Inc.
6.1.9 Seattle Genetics, Inc.
6.1.10 Teva Pharmaceutical Industries Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS